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Abstract
Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, the causative agent of coronavirus
disease 2019 (COVID-19), may lead to severe systemic inflammatory response, pulmonary damage, and even acute
respiratory distress syndrome (ARDS). This in turn may result in respiratory failure and in death. Experimentally,
acetylcholine (ACh) modulates the acute inflammatory response, a neuro-immune mechanism known as the
inflammatory reflex. Recent clinical evidence suggest that electrical and chemical stimulation of the inflammatory reflex
may reduce the burden of inflammation in chronic inflammatory diseases. Pyridostigmine (PDG), an ACh-esterase
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inhibitor (i-ACh-e), increases the half-life of endogenous ACh, therefore mimicking the inflammatory reflex. This clinical
trial is aimed at evaluating if add-on of PDG leads to a decrease of invasive mechanical ventilation and death among
patients with severe COVID-19.
Methods: A parallel-group, multicenter, randomized, double-blinded, placebo-controlled, phase 2/3 clinical trial to test
the efficacy of pyridostigmine bromide 60 mg/day P.O. to reduce the need for invasive mechanical ventilation and
mortality in hospitalized patients with severe COVID-19.
Discussion: This study will provide preliminary evidence of whether or not -by decreasing systemic inflammation- addon PDG can improve clinical outcomes in patients with severe COVID-19.
Trial registration: ClinicalTrials.gov NCT04343963 (registered on April 14, 2020).
Keywords: COVID-19, SARS-Cov-2, Mortality, Invasive mechanical ventilation, Immunomodulation, Pyridostigmine, ACh,
Inflammatory reflex, Placebo-controlled trial

Background
Severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) infection, the causative agent COVID-19, may result in severe systemic inflammatory response. About one
third of hospitalized patients with COVID-19 develop
acute respiratory distress syndrome (ARDS) [1], while 17%
require invasive mechanical ventilation associated to a
high mortality rate [2]. The two main causes of death in
patients with severe COVID-19 are respiratory and
multiple-organ failure as a result of overwhelming inflammatory response [3, 4]. Therefore, patients with severe
COVID-19 will theoretically benefit from therapeutic interventions that modulate the inflammatory response [5].
Pyridostigmine, an acetylcholinesterase inhibitor (i-ACh-e),
increases acetylcholine (ACh) half-life by inhibiting its peripheral degradation. Pyridostigmine has been used for decades in
the symptomatic treatment of myasthenia gravis [6] and as
pre-exposure prophylaxis against nerve gas (chemical) warfare
[7]. Pyridostigmine has well-characterized pharmacokinetic
and safety profiles. Recently, pyridostigmine has been shown
to reduce persistent inflammation in people living with
HIV-1 infection [8–10]. The proposed anti-inflammatory
effect occurs after the ACh binds to nicotinic receptors on
the surface of immune cells and this interaction causes a
decrease in the production of pro-inflammatory cytokines.
This so-called inflammatory reflex, originally described in
response to vagus nerve stimulation [11], leads to the release of ACh with a resulting reduction in acute [12] and
chronic inflammation [13].
Our primary objective is to evaluate whether or not
add-on pyridostigmine to best medical management of
hospitalized COVID-19 patients will result in reduced
need for invasive mechanical ventilation and death.
Methods/design
Aim, study design and settings

Our aim is to tests the efficacy of Pyridostigmine use as
an immunomodulator to reduce the incidence of

complications leading to critical illness or death in hospitalized adults with severe COVID-19. In order to test
this, we propose a randomized, double-blinded, placebocontrolled trial. Participants will be randomly allocated
in a 1:1 ratio to receive either oral pyridostigmine at a
dose of 60 mg/day or a matching placebo for a maximum of 14 days in parallel groups. We will compare the
need of invasive mechanical ventilation and fatality rates
during the 28 days following randomization (Fig. 1).
Unblinding will be permissible in case of severe adverse
events at the request of the treating group of physicians,
or at the request of the external Data and Safety Monitoring Board (DSMB).
The study is planned in two parts: a phase 2 aimed at
determining security, followed by a phase 3 part aimed
at evaluating the effect -or lack thereof- of pyridostigmine in patients with severe COVID-19. Phase 2 started
recruiting on 5 May 2020. During the security (phase 2)
part, we aimed at evaluating the safety and feasibility of
the study and explore in a preliminary way the magnitude of the effect of the intervention. Safety was evaluated according to the frequency of outcomes as well as
of reported adverse events. Enrollment for the security
phase was limited to patients hospitalized at Instituto
Nacional de Ciencias Médicas y Nutrición Salvador
Zubirán (INCMNSZ) in Mexico City. On 4 July 2020, a
pre-appointed DSMB performed an ad interim analysis
after the first 44 participants (10% of the calculated sample) had been recruited and, as results derived from this
security part indicated that pyridostigmine was not associated with an increased frequency of outcomes or adverse events (safety outcome), the DSMB recommended
to proceed to a multi-center, phase 3 trial. During this
ongoing phase 3 component of the RCT, the primary
outcome to be evaluated will be a composite outcome
including 1) the requirement of invasive mechanical ventilation, 2) an increase in the SOFA scale ≥2 points, or
3) death.
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Table 1 Inclusion criteria
1) Adults (≥18 years old),
2) Confirmed SARS-CoV-2 infection based on a positive RT-PCR test
3) Requiring in-hospital care
4) Imaging study compatible with pneumonia,
5) At least one of the following criteria
a). Dyspnea
b). Lung infiltrates occupying > 50% of lung fields by CT scan
c) PaO2/FiO2 ratio < 300 mmHg
d). Peripheral oxygen saturation (SpO2) < 90% while breathing room
air, a ≥ 3% drop in baseline SpO2, or the need of increased flow rates
of supplemental oxygen in the case of chronic hypoxia; and the need
for supplemental oxygen therapy according to the treating medical
team’s judgment.
e). Alteration of one or more of the following laboratory parameters
• D-dimer > 1 μg/mL
• Ferritin level > 300 ng/mL
• C-reactive protein (CRP) > 3 mg/L
• Lactate dehydrogenase (LDH) > 245 U/L
• Lymphopenia, defined as < 800 lymphocytes/uL
• Creatine kinase (CK) level > 800 IU/L

participation in clinical trials of any kind in the previous
28 days.
Fig. 1 The PISCO trial (Pyridostigmine in Severe COVID-19) study
design and schedule of follow-up visit

The DSMB also suggested to repeat an ad interim analysis every time a 10%-recruiting milestone is reached.

Study population

We are including adult (≥18-year-old), hospitalized patients with confirmed SARS-CoV-2 infection based on a
positive RT-PCR test for SARS-CoV-2 RNA in a respiratory specimen (nasopharyngeal or nasal swab) and an
imaging study compatible with pneumonia, and at least
one high-risk criteria of death (see Table 1).
Exclusion criteria include one or more of the following: allergy to pyridostigmine; pregnancy or breastfeeding status; concomitant autoimmune disease; diagnosed
immunodeficiencies (including HIV infection); need for
mechanical ventilation, admission to the ICU, or meeting criteria for septic shock before providing signed, informed consent; inability to receive orally or enterally
administered drugs; use of immunosuppressants or
immune-modulators (including chemotherapy and corticosteroids) in the preceding 28-day period unless recommended by the treatment medical team as part of the
therapeutic approach for SARS-CoV-2 infection; and

Procedures
Randomization

Participants will be randomized in a 1:1 ratio, with parallel assignment to receive either placebo or pyridostigmine as an add-on medical treatment to the best
medical care available for severe COVID-19 in participating centers. The block-randomization process will be
performed using the publicly available online resource
(www.randomizer.org).
Intervention

Patients in the treatment group will receive Pyridostigmine Bromide, 60 mg/day per os. Participants randomized to the control group will receive matching placebo
(identical in appearance) made of pharmaceutical grade
starch. Participants will be receiving the assigned intervention until the occurrence of either 1) any of the prespecified outcomes; 2) hospital discharge; or 3) a maximum period of 14 in-hospital days (Fig. 2).
Outcomes and definition of variables

The primary outcomes are a composite of requirement
of invasive mechanical ventilation, an increase of ≥2
points in the SOFA scale, or all-cause mortality, during
the 28-day period following enrollment; and, 2) safety of
the study drug. The secondary outcome is the change in
interleukin (IL)-6 levels (Δ IL-6) between baseline
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Fig. 2 Protocol Activities. All timepoints are counted from enrollment (Baseline). Arrows indicate specific actions to be performed at each
predefined timepoint. Patients who are discharged from hospital before day 14 are not required to return for blood sampling. Abbreviations:
ABG: arterial blood gases; IL-6: interleukin 6

samples and those taken on days 3, 5, 7, and 14 (for an
outline of the protocol, please refer to Fig. 2; for the
timeline of interventions and measurements, please refer
to Table 2).
We will collect demographic information from participants at baseline, including age, sex assigned at birth, presence of comorbidities which will include diabetes mellitus,
systemic arterial hypertension, obesity, cardiovascular disease, and lung disease, and other chronic medical conditions from the clinical charts. Safety of the intervention will
be actively evaluated by daily interrogation of the following

common adverse effects of pyridostigmine [14]: abdominal
pain or cramps; diarrhea; nausea, vomiting, or both; hypersalivation/drooling; urinary incontinence; muscle weakness
or fasciculations; and, blurred vision. On day 28, patients
will be contacted by telephone to assess their vital and
functional status (Fig. 2; Table 2). All collected data will be
safeguarded on a coded database with access limited to project investigators. Only the principal investigators and the
DSMB will have access to the final trial dataset. The final
results will be published for generalized access, regardless
of the outcome.

Table 2 Scheduled protocol activities
Baseline

Day 3

Day 5

Day 7

Day 14

X

X

X

X

X

X

X

X

X

X

Eligibility preliminary assessment

X

Eligibility confirmation

X

Informed consent & enrollment

X

Study medication supply

X

Adverse-effect assessmenta

Day 28

a

Laboratory evaluations
• D-dimer
• Ferritin

X

X

X

X

X

• CPK

X

X

X

X

X

• Fibrinogen

X

X

X

X

X

• Creatinine

X

X

X

X

X

• Bilirubin

X

X

X

X

X

• CBC

X

X

X

X

X

• ABG

X

Storage of samples for posterior pooled analysisa
• IL-6 measurement

X

X

X

X

X

• Mass cytometry

X

X

X

X

X

Follow-up phone call
a

X

Blood sampling will be performed only while participants are hospitalized. Protocol does not require participants to return for further blood sampling after
hospital discharge. Abbreviations: CBC Complete blood count, ABG Arterial blood gases, IL-6 Interleukin 6
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Study centers

Currently, recruiting for this study is undergoing at,
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán (INCMNSZ), and Instituto Nacional de
Cardiología Ignacio Chávez, two COVID-19-designated
Hospitals in Mexico City, Mexico.
Sample size
First (security) phase

We estimate that a sample size of 40 participants (20 in
each group) would produce a one-sided 80% confidence
limit that would exclude us finding a 10%-point difference that would be statistically significant in the
complete trial [15]. However, calculating a 10% loss, we
will recruit 44 participants for this part of the study.
Second phase

We estimate that a sample size of 436 participants (218
per group) estimating a 10% reduction in the occurrence
of the primary outcome in the intervention group to be
clinically significant. Based on recent evidence from
China, we estimate that 25% of patients hospitalized with
severe SARS-CoV-2 infection will develop complications
leading to the need of invasive mechanical ventilation or
death [16] Accordingly, we estimate that this sample size
will allow us to identify with an 80% power a reduction
in the need of invasive mechanical ventilation or death
of 10% in the group receiving pyridostigmine in comparison with the group on placebo, using a two-sided ttest at the 0.05 significance level.
Statistical considerations

Primary analysis will be performed by intention-to-treat
analysis comparing the proportion of outcome events
between groups using X2 test. We will also compare
point estimates and its corresponding confidence intervals between groups. In a secondary analysis, we will use
multivariate logistic regression models to explore
variables associated with the primary outcomes.
Study status

This is an ongoing study. Recruiting started on 5 May
2020; at submission, we have recruited 86 participants.
No results have been made available, and the therapeutic
arms remain double blinded. Therefore, no results have
been submitted for publication or published.

Discussion
Here, we propose to evaluate the potential usefulness of
pyridostigmine as add-on therapy to best medical care of
patients admitted to a hospital due to severe COVID-19.
Recent evidence indicates that between 25 and 33% of patients hospitalized for COVID-19 required care in intensive care units (ICU) for severe hypoxemia. The reported
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mortality in those first cases that required hospital management is 15%, but in those with severe disease, the reported mortality is between 38 and 49% [2, 16], and we
assume that it will be similar elsewhere. Severity and mortality of COVID-19 appear to be mediated not by infection, but by the disproportionate inflammatory response
of the host. Hence, finding novel immunomodulatory
strategies is a promising strategy to reduce severity and
mortality of COVID-19. Furthermore, the repurposing of
drugs with well characterized safety profiles and readily
available production lines, might lead to faster development of anti-COVID-19 therapies if proven efficacious in
well-designed, randomized clinical trials.
In mammals, the central nervous system has mechanisms
to control the inflammatory response. During inflammatory
states, the vagus nerve can inhibit the synthesis and release
of inflammatory cytokines [17], thereby reducing both local
damage and mortality secondary to severe systemic
inflammation in murine models as diverse as sepsis,
ischemia and re-perfusion damage, or obesity [18–21].
The vagus nerve can be stimulated electrically and
chemically. Chemical stimulation using cholinergic agonists has shown promising effects in murine and cellular models of inflammation [12, 21].
Acetylcholine esterase inhibitors (i-ACh-e) are a
family of drugs used regularly by millions of patients,
including older adults with Alzheimer disease and
other dementias, as well as in patients with myasthenia
gravis and dysautonomia [6, 22–25]. These drugs inhibit the enzymatic degradation of endogenous ACh,
resulting in greater bioavailability and, therefore, an
increase in the possibility of binding to both nicotinic
and muscarinic receptors. In addition to the approved uses
of i-ACh-e in human pathology, there is evidence in various
murine models of their efficacy in experimental sepsis and
severe inflammatory response [12, 19, 21], suggesting that
i-ACh-e drugs have a potential immunomodulatory effect
in patients with severe systemic inflammatory response
syndrome. Pyridostigmine, an acetylcholinesterase inhibitor, has been previously shown to decrease inflammation in people living with human immunodeficiency
virus (HIV) infection [8–10]; therefore, it is possible
that Pyridostigmine may lead to a decrease in the production of pro-inflammatory cytokines in patients with
COVID-19 at high risk of severe disease.
Regarding safety concerns, at the proposed dose of
Pyridostigmine, the rate of adverse events is less than 5–
6% with no reported serious adverse effects [14]. From
this perspective, we consider that pyridostigmine can
function as an immunomodulator and reduce morbidity
and mortality in these patients. The reduction in the frequency of the need for mechanical ventilation would
contribute to reducing mortality and the demand for
these services.

Fragoso-Saavedra et al. BMC Infectious Diseases

(2020) 20:765

Abbreviations
SARS-CoV-2: Severe acute respiratory syndrome coronavirus 2; COVID19: Coronavirus Associated Disease 2019; ARDS: Acute Respiratory Distress
Syndrome; MV: Invasive Mechanical Ventilation; ACh: Acetylcholinesterase
Inhibitor; HIV-1: Human Immunodeficiency Virus Type 1; PISCO trial
: Pyridostigmine in Severe COVID-19; INCMNSZ: Instituto Nacional de Ciencias
Médicas y Nutrición Salvador Zubirán; SOFA: Sequential Organ Failure
Assessment score; ICU: Intensive Care Unit; IL-6: Interleukin-6; i-AChe: Acetylcholine esterase inhibitors

Acknowledgements
Not applicable.

Authors’ contributions
JCC, PFBZ, JSM and SIVF designed the study. SFS, DAIN, PFBZ and SIVF wrote
the manuscript. YCV, JJC and PFBZ helped with methodological and statistical
design. SFS, DAIN, IN, PFBZ, AQV, HBGG, SLCM, BMAC, SAM, VLM, AGD, and BCR
made suggestions and helped in the experimental design. All authors have
read and approved the manuscript.

Funding
This study is funded by peer-reviewed, competitive grants from Consejo
Nacional de Ciencia y Tecnología (CONACyT): Grants 289788 and 311783,
both to SIVF.

Availability of data and materials
The final datasets will be made publicly available in the final manuscripts,
supplemental materials, or public repositories. All protocol documents are
available in Spanish upon reasonable requests.

Ethics approval and consent to participate
This study is being carried out in accordance with the recommendations
of the institutional Ethics in Human Research Committees. All
participants will have given written informed consent to one of the
study investigators in accordance with the Declaration of Helsinki. The
protocol was approved by the Ethics in Human Research Committees of
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán (INCM
NSZ), and Instituto Nacional de Cardiología Ignacio Chávez, both in
Mexico City, Mexico; and Comisión Federal para la Protección contra
Riesgos Sanitarios (COFEPRIS), the Federal Mexican pharmacological
regulatory commission.

Consent for publication
Not applicable.

Competing interests
Pablo F Belaunzarán-Zamudio is an Associated Editor for the HIV and coinfections section of BMC Infectious Diseases.
Author details
1
Programa de Estudios Combinados en Medicina (MD/PhD program),
Universidad Nacional Autónoma de Mexico, Mexico City, Mexico.
2
Departamento de Neurología, Instituto Nacional de Ciencias Médicas y
Nutrición Salvador Zubirán, Mexico City, Mexico. 3Escuela Nacional de
Medicina y Ciencias de la Salud, Instituto Tecnológico y de Destudios
Superiores de Monterrey, Monterrey, Mexico. 4Internal Medicine Residency
Training Program, Instituto Nacional de Ciencias Médicas y Nutrición
Salvador Zubirán, Mexico City, Mexico. 5Departamento de Infectología,
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico
City, Mexico. 6Departamento de e Inmunología y Reumatología, Instituto
Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City,
Mexico. 7Division of AIDS, National Institute of Allergy and Infectious
Diseases, National Institutes of Health, Rockville, MD, USA. 8Center for
Biomedical Science, Feinstein Institute for Medical Research, Manhasset, NY,
USA.

Page 6 of 7

Received: 19 August 2020 Accepted: 7 October 2020

References
1. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of
patients infected with 2019 novel coronavirus in Wuhan, China. Lancet.
2020;395:497–506.
2. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors
for mortality of adult inpatients with COVID-19 in Wuhan, China: a
retrospective cohort study. Lancet. 2020;6736:1–9. https://doi.org/10.1016/
S0140-6736(20)30566-3.
3. Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality
due to COVID-19 based on an analysis of data of 150 patients from Wuhan,
China. Intensive Care Med. 2020;46:846–8.
4. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. COVID19: consider cytokine storm syndromes and immunosuppression. Lancet.
2020;6736:19–20. https://doi.org/10.1016/S0140-6736(20)30628-0.
5. Valdés-Ferrer SI. The challenges of long-term sepsis survivors: when
surviving is just the beginning. Rev Investig Clin. 2014;66:439.
6. Gilhus NE, Verschuuren JJ. Myasthenia gravis: subgroup classification and
therapeutic strategies. Lancet Neurol. 2015;14:1023–36. https://doi.org/10.
1016/S1474-4422(15)00145-3.
7. Keeler JR, Hurst CG, Dunn MA. Pyridostigmine used as a nerve agent
pretreatment under wartime conditions. JAMA J Am Med Assoc. 1991;266:
693–5.
8. Valdés-Ferrer SI, Crispín JC, Belaunzarán PF, Cantú-Brito CG, Sierra-Madero J,
Alcocer-Varela J. Acetylcholine-esterase inhibitor pyridostigmine decreases T
cell overactivation in patients infected by HIV. AIDS Res Hum Retrovir. 2009;
25:749.
9. Valdés-Ferrer SI, Crispín JC, Belaunzarán-Zamudio PF, Rodríguez-Osorio CA,
Cacho-Diaz B, Alcocer-Varela J, et al. Add-on Pyridostigmine enhances
CD4+T-cell recovery in HIV-1-infected immunological non-responders: A
proof-of-concept study. Front Immunol. 2017;8:1301.
10. Robinson-Papp J, Nmashie A, Pedowitz E, George MC, Sharma S, Murray J,
et al. The effect of pyridostigmine on small intestinal bacterial overgrowth
(SIBO) and plasma inflammatory biomarkers in HIV-associated autonomic
neuropathies. J Neuro-Oncol. 2019;25:551–9.
11. Borovikova LV, Ivanova S, Zhang M, Yang H, Botchkina GI, Watkins LR, et al.
Vagus nerve stimulation attenuates the systemic inflammatory response to
endotoxin. Nature. 2000;405:458–62.
12. Rosas-Ballina M, Valdés-Ferrer SI, Dancho ME, Ochani M, Katz D, Cheng KF,
et al. Xanomeline suppresses excessive pro-inflammatory cytokine responses
through neural signal-mediated pathways and improves survival in lethal
inflammation. Brain Behav Immun. 2015;44:19–27.
13. Koopman FA, Chavan SS, Miljko S, Grazio S, Sokolovic S, Schuurman PR,
et al. Vagus nerve stimulation inhibits cytokine production and attenuates
disease severity in rheumatoid arthritis. Proc Natl Acad Sci U S A. 2016;113:
8284–9.
14. Almog S, Winkler E, Amitai Y, Dani S, Shefi M, Tirosh M, et al. Acute
pyridostigmine overdose: a report of nine cases. Isr J Med Sci. 1991;27:659–63
http://www.ncbi.nlm.nih.gov/pubmed/1757242.
15. Cocks K, Torgerson DJ. Sample size calculations for pilot randomized trials: a
confidence interval approach. J Clin Epidemiol. 2013;66:197–201.
16. Wu Z, McGoogan JM. Characteristics of and important lessons from the
coronavirus disease 2019 (COVID-19) outbreak in China: summary of a
report of 72 314 cases from the Chinese Center for Disease Control
and Prevention. Jama. 2019;2020:3–6. https://doi.org/10.1001/jama.2020.
2648.
17. Chavan SS, Tracey KJ. Essential Neuroscience in Immunology. J Immunol.
2017;198:3389–97.
18. Yeboah MM, Xue X, Duan B, Ochani M, Tracey KJ, Susin M, et al. Cholinergic
agonists attenuate renal ischemia-reperfusion injury in rats. Kidney Int. 2008;
74:62–9. https://doi.org/10.1038/ki.2008.94.
19. Satapathy SK, Ochani M, Dancho M, Hudson LK, Rosas-Ballina M,
Valdes-Ferrer SI, et al. Galantamine alleviates inflammation and other
obesity-associated complications in high-fat diet-fed mice. Mol Med.
2011;17:599.
20. Zaghloul N, Addorisio ME, Silverman HA, Patel HL, Valdés-Ferrer SI, Ayasolla
KR, et al. Forebrain cholinergic dysfunction and systemic and brain
inflammation in murine sepsis survivors. Front Immunol. 2017;8:1673.

Fragoso-Saavedra et al. BMC Infectious Diseases

(2020) 20:765

21. Lehner KR, Silverman HA, Addorisio ME, Roy A, Al-Onaizi MA, Levine Y, et al.
Forebrain cholinergic signaling regulates innate immune responses and
inflammation. Front Immunol. 2019;10:1–11.
22. Mayeux R. Early Alzheimer’s disease. N Engl J Med. 2010;362:2194–201.
https://doi.org/10.1056/NEJMcp0910236.
23. Querfurth HW, LaFerla FM. Alzheimer’s disease. N Engl J Med. 2010;362:329–
44. https://doi.org/10.1056/NEJMra0909142.
24. O’Brien JT, Thomas A. Vascular dementia. Lancet. 2015;386:1698–706.
https://doi.org/10.1016/S0140-6736(15)00463-8.
25. Singer W, Sandroni P, Opfer-Gehrking TL, Suarez GA, Klein CM, Hines S, et al.
Pyridostigmine treatment trial in neurogenic orthostatic hypotension. Arch
Neurol. 2006;63:513–8.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.

Page 7 of 7

